- 著者
- Doyeon Hwang Hyun Kuk Kim Joo Myung Lee Ki Hong Choi Jihoon Kim Tae-Min Rhee Jonghanne Park Taek Kyu Park Jeong Hoon Yang Young Bin Song Jin-Ho Choi Joo-Yong Hahn Seung-Hyuk Choi Bon-Kwon Koo Young Jo Kim Shung Chull Chae Myeong Chan Cho Chong Jin Kim Hyeon-Cheol Gwon Myung Ho Jeong Hyo-Soo Kim The KAMIR Investigators
- 出版者
- The Japanese Circulation Society
- 雑誌
- Circulation Journal (ISSN:13469843)
- 巻号頁・発行日
- pp.CJ-17-1221, (Released:2018-02-28)
- 参考文献数
- 31
- 被引用文献数
- 14
Background:There has been debate regarding the added benefit of high-intensity statins compared with low-moderate-intensity statins, especially in patients with acute myocardial infarction (AMI).Methods and Results:The Korea Acute Myocardial Infarction Registry-National Institutes of Health consecutively enrolled 13,104 AMI patients. Of these, a total of 12,182 patients, who completed 1-year follow-up, were included in this study, and all patients were classified into 3 groups (no statin; low-moderate-intensity statin; and high-intensity statin). The primary outcome was major adverse cardiac event (MACE) including cardiac death, non-fatal MI, and repeat revascularization at 1 year. Both low-moderate-intensity and high-intensity statin significantly reduced low-density lipoprotein cholesterol (LDL-C; all P<0.001). Compared with the no statin group, both statin groups had significantly lower risk of MACE (low-moderate intensity: HR, 0.506; 95% CI: 0.413–0.619, P<0.001; high intensity: HR, 0.464; 95% CI: 0.352–0.611, P<0.001). The risk of MACE, however, was similar between the low-moderate- and high-intensity statin groups (HR, 0.917; 95% CI: 0.760–1.107, P=0.368). Multivariable adjustment, propensity score matching, and inverse probability weighted analysis also produced the same results.Conclusions:When adequate LDL-C level is achieved, patients on a low-moderate-intensity statin dose have similar cardiovascular outcomes to those on high-intensity statins.
- 著者
- Albert Youngwoo Jang Minsu Kim Pyung Chun Oh Soon Yong Suh Kyounghoon Lee Woong Chol Kang Ki Hong Choi Young Bin Song Hyeon-Cheol Gwon Hyo-Soo Kim Woo Jung Chun Seung-Ho Hur Seung-Woon Rha In-Ho Chae Jin-Ok Jeong Jung Ho Heo Junghan Yoon Soon Jun Hong Jong-Seon Park Myeong-Ki Hong Joon-Hyung Doh Kwang Soo Cha Doo-Il Kim Sang Yeub Lee Kiyuk Chang Byung-Hee Hwang So-Yeon Choi Myung Ho Jeong Chang-Wook Nam Bon-Kwon Koo Seung Hwan Han
- 出版者
- The Japanese Circulation Society
- 雑誌
- Circulation Journal (ISSN:13469843)
- 巻号頁・発行日
- vol.86, no.9, pp.1365-1375, 2022-08-25 (Released:2022-08-25)
- 参考文献数
- 17
- 被引用文献数
- 1 1
Background: Differences in the impact of the 1- or 2-stent strategy in similar coronary bifurcation lesion conditions are not well understood. This study investigated the clinical outcomes and its predictors between 1 or 2 stents in propensity score-matched (PSM) complex bifurcation lesions.Methods and Results: We analyzed the data of patients with bifurcation lesions, obtained from a multicenter registry of 2,648 patients (median follow up, 53 months). The patients were treated by second generation drug-eluting stents (DESs). The primary outcome was target lesion failure (TLF), composite of cardiac death, target vessel myocardial infarction (TVMI), and ischemia-driven target lesion revascularization (TLR). PSM was performed to balance baseline clinical and angiographic discrepancies between 1 and 2 stents. After PSM (N=333 from each group), the 2-stent group had more TLRs (hazard ratio [HR] 3.14, 95% confidence interval [CI] 1.42–6.97, P=0.005) and fewer hard endpoints (composite of cardiac death and TVMI; HR 0.44, 95% CI 0.19–1.01, P=0.054), which resulted in a similar TLF rate (HR 1.40, 95% CI 0.83–2.37, P=0.209) compared to the 1-stent group. Compared with 1-stent, the 2-stent technique was more frequently associated with less TLF in the presence of main vessel (pinteraction=0.008) and side branch calcification (pinteraction=0.010).Conclusions: The 2-stent strategy should be considered to reduce hard clinical endpoints in complex bifurcation lesions, particularly those with calcifications.
- 著者
- Ki Hong Choi Jeong Hoon Yang David Hong Taek Kyu Park Joo Myung Lee Young Bin Song Joo-Yong Hahn Seung-Hyuk Choi Jin-Ho Choi Su Ryeun Chung Yang Hyun Cho Dong Seop Jeong Kiick Sung Wook Sung Kim Young Tak Lee Hyeon-Cheol Gwon
- 出版者
- The Japanese Circulation Society
- 雑誌
- Circulation Journal (ISSN:13469843)
- 巻号頁・発行日
- vol.84, no.9, pp.1502-1510, 2020-08-25 (Released:2020-08-25)
- 参考文献数
- 27
- 被引用文献数
- 15 27
Background:Although there is an increase in the use of mechanical circulatory support devices to rescue patients with acute myocardial infarction (AMI) complicated by refractory cardiogenic shock (CS), the optimal timing of the application remains controversial. Therefore, this study aimed to compare the clinical outcomes between venoarterial-extracorporeal membrane oxygenation (VA-ECMO) insertion before and after coronary revascularization in AMI patients with refractory CS.Methods and Results:A total of 253 patients with AMI who underwent revascularization therapy with VA-ECMO were included. The study population was stratified into extracorporeal cardiopulmonary resuscitation (E-CPR) before revascularization (N=106, reference cohort) and refractory CS without E-CPR before revascularization (n=147, comparison cohort). Patients with refractory CS but without E-CPR before revascularization were further divided into VA-ECMO before revascularization (N=50) and VA-ECMO after revascularization (n=97). The primary endpoint was a composite of in-hospital mortality, left ventricular assist device implantation, and heart transplantation. The primary endpoint occurred in 60 patients (40.8%) of the comparison cohort and 51 patients (48.1%) of the reference cohort. Among the comparison cohort, the primary endpoint was significantly lower in VA-ECMO before revascularization than in VA-ECMO after revascularization (32.0% vs. 49.5%, OR 0.480, 95% CI 0.235–0.982, P=0.045). A similar trend was observed after a 1-year follow up.Conclusions:Early initiation of VA-ECMO before revascularization therapy might improve clinical outcomes in patients with AMI complicated by refractory CS.